Medtronic expects to report high-single-digit growth in adjusted profit in the back half of the fiscal year, as the negative impact from foreign-currency fluctuations abates.
The company is looking "aggressively at dynamically pricing" in markets with negative foreign currency impacts, interim CFO Gary Corona said on a call with analysts.
The Ireland-based company raised the lower end of its 2025 adjusted profit forecast to $5.44 per share from $5.42 earlier, keeping the upper end at $5.50. The new midpoint of $5.47 is slightly higher than analysts' estimates of $5.45, according to data compiled by LSEG.
It posted adjusted profit of $1.26 per share for the second quarter, compared with estimates of $1.25.